Unknown

Dataset Information

0

Sources of error in measurement of minimal residual disease in childhood acute lymphoblastic leukemia.


ABSTRACT:

Introduction

The level of minimal residual disease (MRD) in marrow predicts outcome and guides treatment in childhood acute lymphoblastic leukemia (ALL) but accurate prediction depends on accurate measurement.

Methods

Forty-one children with ALL were studied at the end of induction. Two samples were obtained from each iliac spine and each sample was assayed twice. Assay, sample and side-to-side variation were quantified by analysis of variance and presumptively incorrect decisions related to high-risk disease were determined using the result from each MRD assay, the mean MRD in the patient as the measure of the true value, and each of 3 different MRD cut-off levels which have been used for making decisions on treatment.

Results

Variation between assays, samples and sides each differed significantly from zero and the overall standard deviation for a single MRD estimation was 0.60 logs. Multifocal residual disease seemed to be at least partly responsible for the variation between samples. Decision errors occurred at a frequency of 13-14% when the mean patient MRD was between 10-2 and 10-5. Decision errors were observed only for an MRD result within 1 log of the cut-off value used for assessing high risk. Depending on the cut-off used, 31-40% of MRD results were within 1 log of the cut-off value and 21-16% of such results would have resulted in a decision error.

Conclusion

When the result obtained for the level of MRD is within 1 log of the cut-off value used for making decisions, variation in the assay and/or sampling may result in a misleading assessment of the true level of marrow MRD. This may lead to an incorrect decision on treatment.

SUBMITTER: Latham S 

PROVIDER: S-EPMC5626434 | biostudies-literature | 2017

REPOSITORIES: biostudies-literature

altmetric image

Publications

Sources of error in measurement of minimal residual disease in childhood acute lymphoblastic leukemia.

Latham Sue S   Hughes Elizabeth E   Budgen Bradley B   Mechinaud Francoise F   Crock Catherine C   Ekert Henry H   Campbell Peter P   Morley Alexander A  

PloS one 20171003 10


<h4>Introduction</h4>The level of minimal residual disease (MRD) in marrow predicts outcome and guides treatment in childhood acute lymphoblastic leukemia (ALL) but accurate prediction depends on accurate measurement.<h4>Methods</h4>Forty-one children with ALL were studied at the end of induction. Two samples were obtained from each iliac spine and each sample was assayed twice. Assay, sample and side-to-side variation were quantified by analysis of variance and presumptively incorrect decisions  ...[more]

Similar Datasets

| S-EPMC6854698 | biostudies-literature
| S-EPMC4808717 | biostudies-literature
| S-EPMC5352064 | biostudies-literature
| S-EPMC3290726 | biostudies-literature
| S-EPMC4486228 | biostudies-literature
| S-EPMC8680540 | biostudies-literature
| S-EPMC3122946 | biostudies-literature
| S-EPMC6649800 | biostudies-literature
| S-EPMC3537310 | biostudies-literature
| S-EPMC8069391 | biostudies-literature